检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:祁洁[1] 邹士涛[2] 李晓庆[2] Qi Jie;Zou Shitao;Li Xiaoqing(Department of Thyroid & Breast Surgery,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215001,China;Suzhou Cancer Center Core Laboratory,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215001,China)
机构地区:[1]南京医科大学附属苏州医院甲状腺、乳腺外科,苏州215001 [2]南京医科大学附属苏州医院肿瘤中心实验室,苏州215001
出 处:《中华内分泌外科杂志》2019年第2期103-106,共4页Chinese Journal of Endocrine Surgery
基 金:苏州市科技局应用基础研究计划(SYS201571).
摘 要:目的探讨肿瘤异常糖链糖蛋白(tumor abnormal protein,TAP)在乳腺癌早期诊断中的临床价值。方法收集2016年5月至2016年12月在南京医科大学附属肿瘤外科就诊,经明确病理诊断的初诊乳腺癌女性患者53例为研究组,同期65例正常体检人群为对照组,比较TAP的阳性率差异。比较乳腺癌不同临床病理参数之间的TAP表达情况。结果65例对照组中无一例TAP阳性,而乳腺癌组TAP阳性率高达83.02%,两者比较差异有统计学意义(P<0.001)。53例乳腺癌中,PR阴性的患者TAP阳性率(100.00%)明显高于PR阳性患者(73.53%),差异有统计学意义(P=0.019)。不同年龄、不同临床分期、有无淋巴结转移及ER、C-erbB2、Ki67的不同表达情况之间的TAP阳性率无明显差异。结论TAP检测对乳腺癌的早期筛查有一定价值,且不同孕激素状态的TAP表达存在差异,为乳腺癌的诊断提供临床参考。Objective To explore the clinical application value of serum tumor abnormal protein (TAP) in early diagnosis of breast cancer. Methods The serum TAP level was determined in 53 hospitalized patients with breast cancer and 65 cases of normal physical examination population as the control group. We further compared the positive rate of TAP in the two groups and the expression level of TAP between different clinical pathological parameters in breast cancer group. Results There was no case of TAP positive in the control group, while the positive rate of TAP was as high as 83.02% in breast cancer group. TAP positive rate of the patients with negative PR (100.00%) was significantly higher than that of PR positive patients (73.53%)(P=0.019). However there was no significant difference of TAP positive rate between patients with different ages, clinical stages, lymph node metastasis and the different expression of ER, C-erbB2 and Ki67. Conclusion It might be clinically valuable to use TAP expression level as a screening marker for breast cancer in combination with the breast cancer hormone PR.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.97